than in adenocarcinomas, were closely associated with lymph node metastasis and TNM stage, and affected patients' prognoses.
Introduction
CD44, an important but unclassified adhesion molecule, is a major ligand of hyaluronan. The abnormal expression of some forms of CD44 can significantly increase the metastatic capacities of malignant tumor cells and is closely associated with tumor metastasis [1] [2] [3] . CD44s play an important role as tumor-promoting oncoproteins in early localized ampullary adenocarcinoma, while CD44 variants were correlated with advanced cancer and recurrent disease [4] . Recent studies have suggested that CD44 is probably a type of stem cell marker and useful as a diagnostic and prognostic tool in many cancers, including non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, and oral cancer [2, 5, 6] .
In our previous studies, a novel CD44st gene was cloned from the multidrug-resistant breast cancer cell line MCF-7/Adr. Those studies showed that hyaluronan upregulates the expression of MMP2 and MMP9 by interacting with CD44st, and thus increases the aggressiveness of MCF-7 cells. The CD44st gene is probably also associated with aggressiveness, metastasis, and prognosis of breast cancer [7] [8] [9] .
To investigate the effects of CD44st expression on NSCLC, we compared the expression of CD44st and MMP2 in NSCLC tissues and corresponding adjacent normal tissues from 125 postoperative NSCLC patients. We analyzed the correlation between CD44st and MMP2 expression, and the relationship between the expression of CD44st and MMP2 and the clinical prognosis and pathological
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Summary Background: Abnormal expression of some CD44 molecules in tumor tissues can induce the degradation of the extracellular matrix, and is closely associated with axillary lymph node metastasis, angiogenesis, cancer progression, and drug resistance. Patients and Methods: We measured and confirmed the expression of CD44st and MMP2 mRNAs and proteins in the cancer tissues and adjacent normal tissues of postoperative non-small cell lung cancer (NSCLC) patients with either adenocarcinoma (n = 72) or squamous cell carcinoma (n = 53) using quantitative reverse transcription polymerase chain reaction, gene sequencing, and immunohistochemical analysis. Results: CD44st and MMP2 expression were closely associated with the histopathological classification, lymph node metastasis, and TNM stage of the tumors, and the difference was statistically significant (p < 0.05). The median overall survival (OS) for the high CD44st expression group was 30.52 months (95% confidence interval (CI) 24.02-36.15); for the low expression group it was 43.23 months (95% CI 31.81-52.02) (p = 0.020). The median OS for the high MMP-2 expression group was 30.53 months (95% CI 26.69-33.31); for the low expression group it was 40.06 months (95% CI 33.55-46.45) (p = 0.022). Conclusion: The rates of CD44st and MMP2 expression were higher in squamous cell carcinomas characteristics of the patients. Our study provides the basis for further studies of the CD44st gene.
Patients and Methods
Patients
Paraffin-embedded tissue specimens (n = 125) were collected from NSCLC patients who had undergone radical resection at our hospital between July 2008 and January 2011. 2 histological subtypes of NSCLC, lung adenocarcinoma (n = 72) and lung squamous cell carcinoma (n = 53), were examined. Corresponding adjacent normal tissues were taken from within 5 cm of the primary location and were chosen randomly as negative controls. The expression of both CD44st and MMP2 in NSCLC tissues and its effect on NSCLC were investigated. The study was approved by the ethics committee of our hospital. The patients' clinicopathological parameters included sex, age, smoking, epidermal growth factor receptor (EGFR) status in the patients with adenocarcinoma, histopathological classification, pathological stage, differentiation grade, lymph node status, and tumor size. No patient had received local radiotherapy or chemotherapy preoperatively, and all of the patients were first diagnosed with NSCLC (table 1) . Histological classification was carried out according to the World Health Organization standards, and postoperative pathological staging was done according to the American Joint Committee on Cancer (6th edition) system. The patients were followed-up every 3-6 months for 5 years following the National Comprehensive Cancer Network guideline, and annually thereafter. Any changes in the patients' condition were recorded. 7 patients died of non-cancer-related causes or were lost to follow-up (4 in the high CD44st expression group, and 3 in the low CD44st expression group), and were excluded from analysis. The final number of patients with effective statistics was n = 118. 
Reagents and Equipment
RNA Extraction, Semiquantitative Reverse Transcription PCR, Gene Sequencing
RNA was extracted from paraffin-embedded tissues with the PureLink TM FFPE RNA (K1560-2) Isolation Kit according to the manufacturer's instructions. The primer sequences for CD44st-1 (GenBank accession FJ 216964), MMP2, and the β-actin gene (ACTB), the reaction conditions, and the gene sequencing protocol were as previously described [7] .
Quantitative Reverse Transcription PCR Amplification of CD44st and MMP2
Fluorescent primers were designed for the qPCR analysis of human CD44st-2 (GenBank accession FJ 216964). The primer sequences for CD44st were: forward 5'-CCCTGCTACCAGACACTCA-3'; reverse 5'-TGTTCAC-CAAATGCACCAT-3' (281-bp amplicon). The primer sequences for MMP2 and ACTB were as previously described [7] . The PCR reaction mixture contained 32.0 μl of double-distilled H 2 O (ddH 2 O), 5.0 μl of 10× buffer, 1.0 μl of dNTPs, 4.0 μl of MgCl 2 (25 mM), 2.0 μl each of the forward and reverse primers (10 pM), 2.0 μl of cDNA template, and 2.0 μl of Taq DNA polymerase (5 U/μl) in a total volume of 50 μl. The reaction conditions were initial denaturation at 95 ° C for 30 s, followed by 45 cycles of incubation at 95 ° C for 5 s and at 60 ° C for 1 min. Each gene in each sample was assigned triplicate wells. The values were normalized to ACTB as the internal reference. ΔCt of the tumor tissues = Ct target gene -Ct β-actin . The relative expression data for the target genes were normalized to those of the internal reference gene, ACTB.
Immunohistochemical Analysis
The immunohistochemical procedures were performed according to the kit instructions (SA2001; Zemai Biotech, Shanghai, China). 4 high-power microscopic fields were randomly selected on each slide to count the number of positive cells. If the percentage of positive cells was less than 25%, the score was 1, 26-50% scored 2, 51-75% scored 3, and > 76% scored 4. The staining intensity was scored as follows: 1 = buff, 2 = pale brown, and 3 = dark brown. Positive results were determined from the total score for both parameters: scores 2 (-), scores 3 (+), scores 4-5 (++), and scores 6-7 (+++); 3 was considered negative and > 3 was considered positive.
Statistical Analysis
Statistical analyses were performed using SPSS statistical software, version 16.0 (SPSS Inc.; IBM Corp., Armonk, NY, USA). The χ 2 test was used as two- sample ratio comparison test. The normal distributions of the average ΔCt values for the extracted CD44st and MMP2 mRNAs, measured with quantitative reverse transcription PCR (qRT-PCR), were determined using the KolmogorovSmirnov test with a p value of 0.11 and 0.16, respectively, and groups were distinguished using mean ± standard deviations. The CD44 expression level was detected by immunohistochemical analysis with a value range of 2-7 scores. The relationship between CD44 expression and the average ΔCt values of CD44st mRNA was calculated using Spearman's rank correlation. A multivariate analysis was performed to test the relationship between the expression of CD44st and MMP2 and the patient's clinical characteristics. A bivariate linear correlation analysis was performed to determine the correlation between the expression of CD44st and MMP2 in NSCLC tissues. Disease-free survival (DFS) and overall survival (OS) were measured from the time of diagnosis and analyzed using the Kaplan-Meier method. P values of 0.05 were regarded significant.
Results
qRT-PCR Amplification Curve of CD44st and β-actin mRNA in NSCLC Tissues
In the qRT-PCR amplification curve of CD44st and β-actin mRNA of each specimen as smooth 'S' shape, the number of amplification cycles between multiple holes (Ct values) was less than 0.5 cycles, and the dissolution curve showed a sharp single-peak curve. The qPCR system used in this study had a high veracity and stability (online supplementary figure 1 A-B 
com/?DOI=456669).
A subgroup analysis showed that of the 67 patients who expressed CD44st mRNA and CD44 protein, 53 (79.1%) expressed high levels of MMP2 mRNA and protein, whereas 14 (20.9) expressed low levels. Of the 58 patients who did not express CD44st mRNA and CD44 protein, 6 (10.34%) expressed high levels of MMP2 mRNA and protein and 52 (89.7%) expressed low levels. The difference between the 2 groups was statistically significant (p < 0.001). A significant correlation was also observed between CD44st and MMP2 expression (r = 0.687) (table 2). A further study suggested that the rates of CD44st mRNA as well as CD44 protein and MMP2 expression in lung squamous cell carcinoma tissues were 73.6% (39/53) and 69.8% (37/53), respectively, which were higher than the rates in lung adenocarcinoma tissues at 38.9% (28/72) and 33.3% (24/72), respectively. The difference between the 2 histological types of lung cancer was statistically significant (p < 0.05) (table 3). The gene sequencing data indicated that the sequence of this CD44 gene was identical to the sequence of the CD44st gene that we had previously identified in the MCF-7/Adr cell line.
Correlation Analysis of CD44st and MMP2 mRNA Expression in NSCLC Tissues
The median ΔCt for CD44st when normalized to the internal reference gene (ACTB) in NSCLC tissues was 9.59, and the median ΔCt for MMP2 (after normalization to ACTB) in NSCLC tissues was 9.41. The correlation analysis showed a linear correlation be- 
Relationship between CD44st and MMP2 mRNA Expression and Clinicopathological Characteristics
CD44st and MMP2 expression was closely associated with histopathological classification, lymph node metastasis, and TNM stage of the tumor, and the difference was statistically significant (p < 0.05). There was no significant correlation between CD44st or MMP2 expression and sex, age, smoking, EGRF status (patients with adenocarcinoma), tumor differentiation grade, or tumor size (p > 0.05) (table 1). The tumor differentiation grade was verified to have a relationship with the expression of MMP2 but not CD44st (p < 0.05) (table 1).
Effects of CD44st and MMP-2 Expression on DFS and OS
The expression of CD44st and MMP-2 mRNA in tumor tissues was determined using a ROC curve, and the corresponding maximum of the Youden's index was the optimal cutoff value. The ΔCt cutoff values of CD44st and MMP-2 mRNA were 9.86 and 10.11, respectively. With regard to the effects of CD44st and MMP-2 mRNA expression on the prognosis of postoperative NSCLC patients, results showed that the median DFS was 15.42 months (95% 
Discussion
Our study indicates that CD44st and MMP2 are more frequently expressed in lung squamous cell carcinoma than in lung adenocarcinoma. Other recent studies have shown that CD44 is expressed on the surfaces of bronchial basal cells, alveolar macrophages, and regenerating cuboidal pneumocytes in injured lung, whereas no CD44 expression has been observed in terminally differentiated epithelial cells, such as ciliated or non-ciliated columnar cells of the bronchial epithelium or type 1 flat pneumocytes lining alveolar tissues [10] . In contrast, metaplastic squamous epithelium in the proliferating basal layers of the bronchi displays increased immunoreactivity for CD44, implying that the malignant transformation of squamous cells is closely associated with CD44 expression. However, CD44 expression is generally low in lung adenocarcinoma [11, 12] , and this difference is probably attributable to the heterogeneous histological origin of lung adenocarcinoma.
TNM stage is an independent factor affecting the prognosis of lung cancer patients, and is mainly based on lymph node metastasis, tumor size, and distant metastasis. In our study, CD44st and MMP2 were highly expressed in the tumor tissues of patients with lymph node metastasis, and were associated with the histological classification and TNM stage of the tumors. Our results also suggest that CD44st and MMP2 correlate significantly with the aggressiveness of the tumor. PFS and OS were significantly lower in the high CD44st expression group than in the low expression group. These results imply that tumors with strong CD44st expression are more likely to metastasize and relapse locally. Hence, CD44st expression levels could affect the prognosis of postoperative NSCLC patients.
Previous studies have shown that CD44 genetic polymorphisms are closely associated with NSCLC genesis, bone metastasis, and TNM stage [13, 14] . Independently of the TNM stage, CD44 genetic polymorphisms are predictive of a poor prognosis in postoperative NSCLC patients, especially in those with lung adenocarcinoma [15] . CD44-V6, a member of the CD44 family, was closely correlated with tumor differentiation, histological type, TNM stages, and lymph node metastasis of NSCLC, while it had no significant correlation with tumor size [16] . Another study of CD44 expression reported that CD44 was closely related to lymph node metastasis, distant metastasis, and TNM stage of gastric cancer, and that it was an independent marker and could be used to predict OS [17] . In recent years, research has suggested that the CD44+/CD24-tumor cell phenotype, a type of breast cancer stem cell, was associated with the molecular classification of breast cancer [18] and has a close relationship with invasiveness, proliferation, lymphatic metastasis, and poor prognosis [19, 20] .
Hyaluronan is a major component of the extracellular matrix. Some abnormally expressed CD44 receptors bind hyaluronan, which promotes the secretion of matrix metalloproteinases (MMPs), resulting in extracellular matrix degradation which is closely associated with tumor angiogenesis, axillary lymph node metastasis, and prognosis [21] [22] [23] . It has been reported that during tumor progression, hyaluronan binds to CD44 isoforms which are extensively expressed on the surface of the cell membrane, and mediates the activation of ankyrin and Rho small G protein, further activating the PI3K-AKT signaling pathway. This increases the adhesion, growth, migration, and invasion of tumor cells, ultimately promoting tumor progression [24] . Studies showed that positive MMP-2 expression correlated with the level of CD44v6 protein, which plays a crucial role in tumor progression and may be a significant predictive factor for poor prognosis in cancer patients [25] [26] [27] [28] .
Our study provides further evidence that the CD44st and MMP2 genes are highly expressed in NSCLC tissues but not in adjacent normal tissues. Our correlation analysis indicated a linear correlation between the expression of CD44st mRNA and MMP2 mRNA, suggesting that increased CD44st expression may promote MMP2 expression by interacting with hyaluronan, further enhancing the aggressiveness of the tumor. The results also showed that median DFS and OS were lower in the groups with high CD44st and MMP-2 expression than in the low expression groups. Therefore, CD44st and MMP2 can potentially be used as markers to predict the aggressiveness of the tumors and the prognosis of postoperative NSCLC patients. Furthermore, we found that tumor differentiation grade was correlated with the expression of MMP2 but not CD44st. This phenomenon suggests that different cell signaling pathways may regulate the expression of MMP2 and CD44st in NSCLC cells.
In conclusion, we detected high levels of CD44st and MMP2 expression in NSCLC tissues. The expression of CD44st and MMP2 correlated significantly with lymph node metastasis and TNM stage, and affected the prognosis of postoperative NSCLC patients. Although the sample size was limited, our study suggests that determining the expression of CD44st and MMP2 is a valuable way of predicting the metastatic potential and prognosis of NSCLC. CD44st and MMP2 are also potential therapeutic targets in NSCLC, which warrants further study.
